Feature | March 07, 2013

Echocardiograms for Valvular Regurgitation May Be Overused

The American Society of Echocardiography joins with 16 other specialty groups—releasing a list of “Five Things Physicians and Patients Should Question” at a national event in Washington, D.C

March 7, 2013 — The American Society of Echocardiography (ASE) has released a list of five interventions whose appropriateness physicians and patients should discuss as part of Choosing Wisely, an initiative of the ABIM Foundation, along with Consumer Reports. First in the list, they ask that patients and their doctors talk about the real need for additional echocardiograms when there are only minor signs of heart valve leakage.

Do not order follow up or serial echocardiograms for surveillance after a finding of trace valvular regurgitation on an initial echocardiogram.

As access to healthcare information has become more readily available to concerned patients, a growing number of doctors have become involved in evaluating, ordering and caring for patients with a wider range of heart health problems rather than sending them directly to a specialist to follow these issues. Additionally, the technology associated with medical testing has improved and miniaturized, leading to increased utilization of echocardiography to quickly and painlessly evaluate the patient’s heart. With the increase in testing and improvements in technology, it is now common for physicians to find trace valve regurgitation, or leakage, that in the past no one would have been aware was present. This may lead to anxiety, misleading results and more questions for a patient who has a limited understanding of echo reporting.

Trace regurgitation is a very mild leak of a heart valve, which occurs when a valve does not close tightly, allowing blood to leak backward in your heart. Nearly all of the normal population will have a finding of some trivial or mild degree of regurgitation of one, two or three heart valves on a normal echocardiogram. This is sometimes called “physiologic” regurgitation by the doctor interpreting the echocardiogram. In most cases, a doctor, used to seeing these types of patients, will not even mention this finding to the patient as a way of avoiding the anxiety associated with this disclosure, which would be an essentially normal finding in most patients.

Trace, physiologic, and in most cases, mild regurgitation of the mitral, tricuspid or pulmonic valve reported on an echocardiogram requires no immediate or long term follow up. Following up on these findings with additional testing should only be done if you and your doctor believe you have signs and symptoms of the leakage progressing or getting worse. These signs may include a murmur (an abnormal sound when the doctor listens to your heart), fatigue, chest pain, shortness of breath, or extra, or funny, heart beats.

If a patient has trace regurgitation of the aortic valve, their doctor may choose to follow the regurgitation with future echocardiograms and additional physical examinations.

The goal of Choosing Wisely is to promote conversations between physicians and patients about utilizing the most appropriate tests and treatments and avoiding care that may provide no benefit.

ASE’s testing cardiovascular care scenarios were chosen based on the highest likelihood of improving patient care and reducing inappropriate test use. Leaders in the organization transformed the scenarios into plain language and produced the clinical explanations for each procedure. In particular, ASE’s cardiovascular care experts, reviewed the ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriateness Use Criteria for Echocardiography (AUC), which was published in March 2011.

ASE encourages all medical professionals engaged in cardiovascular care to read the

“Five Things Physicians and Patients Should Question” lists at www.choosingwisely.org, and to engage their patients in conversations about reducing inappropriate tests and procedures with a goal of improving care and avoiding harm.

Consumer Reports, along with a coalition of consumer partner organizations, is also a part of the Choosing Wisely effort and is working with many of the societies to help patients understand the tests and treatments that are right for them.

For more information: www.asecho.org, www.choosingwisely.org

Related Content

common adult CT examinations, computed tomography, diagnostic reference levels, DRLs, radiation dose, achievable dose, AD
News | Radiation Dose Management| February 23, 2017
Using data from the world’s largest computed tomography (CT) dose index registry, researchers have established national...
Mercy, HIMSS 2017, Enterprise Davies Award, health information technology
News | Information Technology| February 21, 2017
Mercy, the fifth largest Catholic healthcare system in the nation, was named a 2016 Healthcare Information and...
News | Cardiac Diagnostics| February 17, 2017
Levels of a protein in the blood associated with heart disease are also linked to early-stage brain damage, according...
deep learning, medical imaging, Signify Research market report, 2021
News | Artificial Intelligence| February 15, 2017
February 15, 2017 — Deep learning, also known as...
Mercator MedSystems, DANCE trial data, ISET, LINC, Bullfrog Micro-Infusion Device
News | Peripheral Arterial Disease (PAD)| February 15, 2017
Mercator MedSystems announced that the national co-principal investigators of the company’s DANCE trial each presented...
Medtronic, IDE approval, IN.PACT Admiral drug-coated balloon, DCB, end-stage renal disease
News | Drug-Eluting Balloons| February 08, 2017
Medtronic plc announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug Administration...
CSI, LIBERTY 360 Study, ISET 2017, six-month data, lower extremity PAD
News | Atherectomy Devices| February 08, 2017
February 8, 2017 — Cardiovascular Systems (CSI) presented six-month data from its LIBERTY 360° post-market study in a
GE Healthcare, Rapiscan stress imaging agent, North America, Rapidscan Pharma Solutions Inc.
News | Pharmaceuticals| February 07, 2017
GE Healthcare’s Life Sciences business announced in January that it acquired Rapidscan Pharma Solutions Inc., which has...
Penn Medicine, heart failure causes, YAP and TAZ proteins, Journal of Clinical Investigation study
News | Heart Failure| February 07, 2017
February 7, 2017 — Of the more than 700,000 Americans who suffer a heart attack each year, about a quarter go on to d
Avinger, VISION Study, two-year outcomes, LINC, Lumivascular technology, Pantheris, OCT-guided atherectomy
News | Atherectomy Devices| February 03, 2017
Avinger Inc. recently announced positive two-year clinical data from the pivotal VISION study of the company’s...
Overlay Init